Cardiac Biotech Solutions Announces Strategic Partnership
In an exciting development for Cardiac Biotech Solutions, Inc. (OTCID: CBSC), the company has reported the receipt of a substantial purchase order from Noventis Medical. This new partnership will enhance the distribution of the MyCardia AT Cardiac Event Monitoring devices, aligning with the company's commitment to improving patient care.
Major Purchase Order Details
The initial order placed by Noventis Medical amounts to $375,000 USD, encompassing 2,500 MyCardia AT devices. Priced at $150 each, this order reflects the growing demand for innovative cardiac monitoring solutions in Central America.
Efficient Delivery Schedule
According to the terms established, Cardiac Biotech Solutions will ship the first set of 1,000 devices immediately upon completion of manufacturing. The remaining inventory of 1,500 units is expected to be delivered within a timeframe of 90 days. This proactive approach aims to ensure that healthcare facilities are promptly equipped with necessary monitoring devices, reinforcing their support for patient health.
Innovative Revenue Model Introduction
In addition to the device sales, CBSC is rolling out a new recurring monthly rental program. This initiative is designed not only for immediate revenue generation but also serves to create a long-term and sustainable income stream.
Details of the Rental Program
This rental program will generate ongoing revenue from the MyCardia AT devices as they are operational in hospitals and healthcare settings. Each rental will encompass the comprehensive use of the device, supported by AWS Cloud-based monitoring software and user-friendly apps accessible on various platforms, including iOS and Android.
Enhancing Global Reach with the MyCardia Platform
Cardiac Biotech Solutions is strategically enhancing the global commercialization of its MyCardia AT cardiac event monitoring platform. This cutting-edge technology integrates lightweight, user-friendly wearables that not only comply with current medical standards but also offer connectivity through AWS Cloud services.
Regulatory Clearances and Future Plans
With regulatory approval already secured in the United States, the company is actively pursuing additional clearances in markets like Canada and China. This strategic movement aligns with CBSC's mission to make advanced cardiac monitoring solutions available to patients worldwide.
About Noventis Medical
Headquartered in Panama City, Noventis Medical stands out as a premier distributor of advanced medical technologies throughout Central America. By prioritizing innovative healthcare solutions, Noventis aims to optimize patient outcomes across various clinical environments.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc. is committed to delivering cutting-edge products and services in the field of non-invasive ambulatory cardiac monitoring. Their innovative EKG devices, combined with interactive cloud-based software and smartphone applications, are designed to enhance patient compliance and provide physicians with accurate data.
Company Contact Information
For more information about their services, potential investors can reach out through the following contact methods:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Frequently Asked Questions
What is the total value of the purchase order with Noventis?
The total order value is $375,000 USD for 2,500 MyCardia AT devices.
How does the rental program revenue work?
CBSC receives one-third of the monthly rental fee from the devices deployed in healthcare facilities.
Where is Noventis Medical based?
Noventis Medical is headquartered in Panama City, Panama.
What is the MyCardia AT platform?
The MyCardia AT platform offers non-invasive cardiac event monitoring with AWS Cloud connectivity and mobile applications.
How can investors contact Cardiac Biotech Solutions?
Investors can contact the company via telephone at (888) 225-0870 or email at investor@cardiacbiotech.com.
